JPRN-jRCT1080220109
Unknown
未知
A randomized phase 2 trial of Irinotecan/Paclitaxel versus Irinotecan/Gemcitabine in patient with stage IIIB/IV non small cell lung cancer.
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yakult Honsha Co.,Ltd.
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically confirmed NSCLC
- •Neither prior chemotherapy nor prior radiotherapy
- •Age between 20 and 74 years old
- •ECOG Performance Status: 0\-1
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A clinical trial to compare tolerabilty and efficiacy (how well the drug works) of following treatments:Blocking liver arteries (chemoembolisation) by beads loaded with irinotecan (chemotherapeutic) and intravenous administration of cetuximab (chemotherapeutic) compared to administration of intravenous cetuximab and irinotecan in patients with k-ras (gene) wild-type tumors.Patients with unresectable liver metastases of colorectal cancer who previously failed pretreatment with 5FU/oxaliplatin and/or 5FU/irinotecan (2nd- or 3rd-line).MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-014728-44-DEMartin Luther Universität Halle-Wittenberg80
Completed
Phase 2
A Randomized, phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small-cell lung cancer HOT1401/NJCLG1401JPRN-UMIN000013882orth Japan Lung Cancer Study Group and Hokkaido Lung Cancer Clinical Study Group80
Active, not recruiting
Phase 1
Medical treatment for patients with cancer of the esophagus or stomachPatients with esophagus or gastric cancer and who are platinum resistant and non-resectabelMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002321-30-DKOdense University Hospital
Recruiting
Not Applicable
Phase II trial of paclitaxel (T) vs Irinotecan(I) in patients with extensive disease (ED) small cell lung cancer (SCLC) as 2nd line chemotherapyNeoplasmsKCT0003330Chung-Ang Univerisity Hospital136
Completed
Phase 2
Randomized phase II study of irinotecan and cisplatin or irinotecan, cisplatin and etoposide in patients with extensive small-cell lung cancerExtensive small-cell lung cancerJPRN-C000000120Division of Medical Oncology, National Cancer Center Hospital110